On July 23, 2025, Shanghai Haoyuan Chemexpress Co., Ltd. (stock code: 688131, hereinafter referred to as "ChemExpress")and UVLEDTEK Group (hereinafter referred to as "UVLEDTEK") officially signed a strategic cooperation agreement in Shanghai. This in-depth collaboration focuses on the innovative application of third-generation wide-bandgap semiconductors in the field of photochemical continuous-flow drug synthesis. By integrating the core strengths of both parties in chemical synthesis and semiconductor photonics, the partnership aims to achieve a qualitative leap in drug production efficiency across momentum transfer, heat transfer, mass transfer, and chemical reaction rates. It will accelerate the pharmaceutical manufacturing industry's transition from traditional batch-based production processes toward a more "continuous, intelligent, and low-carbon" model, setting a new benchmark for global drug research, development, and manufacturing.
Dr. Zheng Baofu, Chairman of ChemExpress (left)
Professor Chen Changqing, Chairman of UVLEDTEK (right)
ChemExpress specializes in offering CRO&CDMO services for pharmaceutical and biotech companies, focusing on small molecules, antibodies and new modalities such as ADCs\XDCs, peptides and PROTACs. It has established comprehensive service capabilities covering "starting materials → intermediates → APIs → finished dosage forms," positioning itself within the top tier of the industry in ADC drug development and CDMO services. To date, the company has served over 990 clients globally, supporting more than 50 CMC projects and over 150 payload-linker projects. From 2019 to 2024, its revenue increased from RMB 409 million to RMB 2.27 billion, maintaining an average annual growth rate of around 40%. ChemExpress continues to drive global pharmaceutical R&D forward with its robust innovation capabilities.
UVLEDTEK stands as a pioneering enterprise in China, uniquely achieving full-spectrum and full-industrial-chain layout in third-generation semiconductor UV LED technology. It possesses a complete technological system spanning from epitaxial material growth to light source system integration. The company's independently developed deep ultraviolet chip technology achieves full-spectrum coverage, with performance metrics such as chip luminous efficiency reaching globally leading levels. With a cumulative total of 325 intellectual property applications, UVLEDTEK has established distinctive core competencies in UV luminous efficiency enhancement, reliability optimization, system integration, and the application of artificial intelligence algorithms. Its products have been widely adopted in critical fields such as new energy vehicles, healthcare, and high-end manufacturing.
Dr. Zheng Baofu, Chairman of ChemExpress:
"The pharmaceutical industry is currently at a critical juncture of technological transformation. Photochemical continuous-flow synthesis technology, with its advantages of high efficiency and environmental sustainability, holds the potential to redefine drug production models. UVLEDTEK's cutting-edge expertise in UV LED chips and system integration perfectly complements ChemExpress's robust CDMO industrialization capabilities. This collaboration will accelerate the application and commercialization of advanced manufacturing technologies in the pharmaceutical sector, helping global partners significantly shorten drug development timelines. It will bring more effective treatment options to patients and drive the industry toward higher-quality development."
Professor Chen Changqing, Chairman of UVLEDTEK:
"UVLEDTEK has been deeply engaged in the semiconductor UV LED field for many years, consistently committed to integrating technological innovation with industrial applications. We believe that in-depth collaboration with ChemExpress in drug synthesis scenarios will effectively overcome the technical bottlenecks of traditional chemical synthesis and promote the standardized, large-scale application of photocatalytic reactions in the pharmaceutical field. The synergy between both parties will not only significantly enhance drug production efficiency and reduce costs but also provide a new pathway for the development of green pharmaceutical processes, injecting strong momentum into the sustainable development of the pharmaceutical industry."
The establishment of this strategic partnership marks a significant step by both parties to integrate complementary resources in the fields of chemical synthesis and semiconductor photonics technology. By jointly exploring technological innovations in photochemical continuous-flow drug synthesis processes utilizing third-generation wide-bandgap semiconductors, the collaboration aims to achieve qualitative improvements in momentum transfer, heat transfer, mass transfer, and chemical reaction efficiency. This effort will drive the transformation of pharmaceutical manufacturing from traditional "batch production" to a more "continuous, intelligent, and low-carbon" model. The partnership not only opens a new chapter in pharmaceutical manufacturing technology innovation but also sets a new benchmark for technological advancement and green development within the industry. It is poised to make a substantial contribution to the progress of the global pharmaceutical sector.
About ChemExpress:
Founded in 2006, Shanghai Haoyuan Chemexpress Co., Ltd. ("ChemExpress", stock code: 688131) specializes in offering CRO&CDMO services for pharmaceutical and biotech companies, focusing on small molecules, antibodies and new modalities such as ADCs\XDCs, peptides and PROTACs. The company ranks among the top tier in the ADC drug R&D and CDMO sectors, having built an integrated service capability covering "starting materials – intermediates – APIs – finished dosage forms." It has served over 990 clients globally, supporting more than 50 CMC projects and over 150 payload-linker projects. From 2019 to 2024, the company's revenue grew from RMB 409 million to RMB 2.27 billion, maintaining an average annual growth rate of approximately 40%. It continues to empower global pharmaceutical R&D with its robust innovation capabilities.
About UVLEDTEK:
UVLEDTEK Group is China's sole chip manufacturer to achieve a full-spectrum and full-industrial-chain layout in semiconductor UV LEDs, possessing a complete technological system spanning from epitaxial material growth to light source system integration. The company has filed a cumulative total of 325 intellectual property applications and has developed core competencies in areas such as UV luminous efficiency enhancement and reliability optimization. Its independently developed UV LED products deliver globally leading performance levels and have been widely adopted in sectors including new energy vehicles, healthcare, and high-end manufacturing, providing robust support for technological advancement and innovative development across various industries.
